Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results

SAN DIEGO, March 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today financial results for the fourth quarter and fiscal year ended December 31, 2011, and provided an update on the DIFICID® (fidaxomicin) launch for the first two months of 2012.

2011 Financial Highlights

  • Total revenues in 2011 were $145 million, compared to $1.5 million in 2010
  • DIFICID net sales in 2011 were $21.5 million, compared to no DIFICID sales in 2010
  • DIFICID net sales in the fourth quarter were $11.0 million

  • "2011 was a highly successful year that saw the FDA approval and U.S. launch of DIFICID as well as European approval. The early launch is highly impactful and we believe interest in DIFICID from physicians, payors and hospitals, coupled with the benefit it can provide patients, will translate into robust growth in product adoption and sales as the launch matures," said Pedro Lichtinger, Optimer's President and CEO. "In 2012 we are starting a series of additional initiatives to support further growth, including a focus on the Long Term Care market, improving access, initiating clinical trials intended to expand our label, and entering new markets including Europe through our collaboration with Astellas and Canada through a direct commercialization effort."

    Fourth Quarter and Fiscal Year 2011 Financials:For the fiscal year 2011 total revenues were $145 million, compared to $1.5 million for the fiscal year 2010. Total revenues for the fourth quarter 2011 were $64.6 million, compared with $156,000 for the fourth quarter 2010. The increases in revenues were primarily due to an upfront payment received from Astellas Pharma Europe in the first quarter and an EMA approval milestone earned in the fourth quarter in connection with the DIFICID license agreement in Europe, as well as the July 18, 2011 commercial launch of DIFICID in the United States.

    DIFICID net product sales were $21.5 million and $11 million for the fiscal year 2011 and fourth quarter, respectively. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

    Selling, general and administrative (SG&A) expense for the fiscal year 2011 was $87.1 million, compared to $17.6 million for the fiscal year 2010. The increase in 2011 was primarily related to the commercial infrastructure build-up for the launch of DIFICID as well as a significant increase in related marketing expenses.  Approximately 100 hospital account managers were hired in mid- 2011 which significantly increased compensation expenses and related personnel costs. In addition, the Company expensed $6.6 million related to the Cubist service fee as part of its co-promotion agreement. SG&A expense for the fourth quarter of 2011 was $33.6 million, compared to $5.7 million for the fourth quarter of 2010. The increase in the fourth quarter was again related to the commercial infrastructure build-up and related marketing expenses, the Cubist service fee, the initial build-up of the Canadian subsidiary's commercial infrastructure, and legal and consulting services related to DIFICID international expansion.  In addition, the fourth quarter of 2011 also included $3.0 million of non-recurring one-time expenses for compensation related matters including $1.8 million of non-cash stock compensation expense.

    R&D expense for the fiscal year 2011 was $43.1 million, compared to $32.8 million for 2010. The increase was primarily due to higher health economics and outcomes research, medical affairs, pharmacovigilance, and publication expenses, as well as higher research and development expense by OBI, our Taiwan subsidiary, for its Phase 2/3 breast cancer clinical trial. The increase was partially offset by a $5.0 million expense in 2010 related to a milestone payment due to Par for the successful completion of the second DIFICID Phase 3 trial. Research and development expense for the fourth quarter of 2011 was $14.0 million, compared to $6.9 million for the fourth quarter of 2010. The increase was related to higher health economics and outcomes research as well as medical affairs expenses, DIFICID life cycle management planning, and preparation for a pediatric clinical trial.

    For the fiscal year 2011, Optimer reported net income of $7.8 million, or $0.17 per share on both a basic and diluted basis, as compared to a net loss for the fiscal year of 2010 of $47.3 million, or ($1.25) per share on both a basic and diluted basis.  

    Net income for the fourth quarter of 2011 was $13.4 million, or $0.29 and $0.28 per share on a basic and diluted basis, respectively, as compared to a net loss for the fourth quarter of 2010 of $11.9 million, or ($0.31) per share, on both a basic and diluted basis.  

    As of December 31, 2011, Optimer held cash, cash equivalents and short-term investments of $110.6 million and had 46,689,951 shares outstanding.

    2012 DIFICID Launch UpdateBetween January 1, 2012 and February 29, 2012, Optimer estimates approximately $11.0 million in DIFICID gross sales, representing 3,931 DIFICID treatments shipped to wholesalers.

    Additionally, as of February 29, 2012:

  • Inventory levels at wholesalers remain within the range of 14 to 28 days of demand
  • Approximately 1,400 hospitals had ordered DIFICID
  • About 65% of hospitals covered by Optimer have reordered DIFICID
  • More than 600 hospitals are estimated to have placed DIFICID on formulary

  • Optimer 2011 and Recent Highlights

  • In December 2011, the EMA granted European marketing approval for DIFICLIR™ (fidaxomicin) tablets.
  • In October 2011, Optimer established a Canadian subsidiary and appointed a country manager to support efforts to sell DIFICID directly into Canadian markets, if approved. In addition, the company filed a New Drug Submission to Health Canada for DIFICID for the treatment of CDAD and was granted a priority review from the Canadian authorities.
  • In July 2011, Optimer announced the commercial launch of DIFICID tablets for the treatment of CDAD in patients 18 years of age and older.
  • In May 2011, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID® (fidaxomicin) tablets for the treatment of CDAD in adults 18 years of age and older.
  • In April 2011, Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID in the U.S. in an effort to accelerate the DIFICID launch. Cubist's 180 hospital-based sales reps combined with Optimer's 100 sales reps are jointly promoting DIFICID to physicians, hospitals, long-term care facilities and other healthcare institutions.
  • In February 2011, Optimer entered into a collaboration agreement with Astellas Pharma Europe Ltd. to develop and commercialize DIFICLIR in Europe and certain other countries in the Middle East, Africa, and the Commonwealth of Independent States.  Under the agreement, Optimer is eligible to receive milestone payments of up to approximately $224 million and of which $69.2 million was received upfront, and a $53.6 million milestone was recorded in the fourth quarter related to the EMA approval. The agreement provides Optimer tiered double-digit royalty payments on net sales of DIFICLIR in the Astellas territories.
  • In February 2011, DIFICID North American Phase 3 trial results were published in The New England Journal of Medicine in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," in the February 3, 2011 issue. In 2011 Optimer also had a series of other publications and presentations at medical and scientific conferences, including the publication of a Subgroup Analysis in the September 1, 2011 issue of Clinical Infectious Diseases demonstrating that DIFICID exhibited higher clinical cure and global cure rates than vancomycin in patients with CDAD receiving concomitant antibiotics.
  • In January 2011, Optimer appointed former Chairman and CEO of Pfizer, Hank McKinnell, Ph.D., to Optimer's Board of Directors and in February 2012 he was appointed Lead Independent Director.

  • Conference Call and WebcastThe Company will host a conference call and webcast to discuss its fourth quarter 2011 and fiscal year 2011 financial results and provide a business overview, including DIFICID® sales, commercialization and development, today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

    The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the "Investors" section of Optimer's website at, where it will be archived for 30 days following the call.  

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at

    Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's expectations of future sales and adoption of DIFICID, projections regarding the results and trends of the DIFICID launch and expected label expansion as a result of new development efforts and clinical trials. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to continue driving adoption and use of DIFICID, the implementation and success of DIFICID growth initiatives and entry into new markets, the ability to expand indications included on DIFICID's label, the ability to successfully complete additional clinical trials and  whether such trials will support an expanded label for DIFICID, whether healthcare professionals will prescribe DIFICID, the extent to which DIFICID receives reimbursement coverage from healthcare payers and government agencies, the extent to which DIFICID will be accepted on additional hospital formularies and the timing of hospital formulary decisions, Optimer's ability to successfully coordinate commercialization efforts with Cubist Pharmaceuticals under its co-promotion agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist and its collaboration agreement with Astellas, the fact that past results may not be predictive of future results or performance, the possibility of alternative means of preventing or treating DIFICID impacting adoption and sales of DIFICID, Optimer's ability, through its third party manufacturers and logistics providers, to maintain a sufficient supply of DIFICID to meet demand, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law. Optimer Pharmaceuticals, Inc. Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2011201020112010Revenues:Product revenue, net

    $   10,959,217$
    -$ 21,511,037$

    53,584,000-122,749,000-Research grants and collaborative agreements

    73,139156,352718,3361,480,362Total revenues

    64,616,356156,352144,978,3731,480,362Operating expenses:Cost of product sales

    909,843-1,525,798-Cost of licensing

    3,310,821-7,584,353-Research and development

    14,011,0596,940,56443,085,30732,797,672Selling, general and administrative

    33,632,5915,706,45587,144,25717,550,883Total operating expenses

    51,864,31412,647,019139,339,71550,348,555Income (loss) from operations

    12,752,042(12,490,667)5,638,658(48,868,193)Interest income and other, net

    63,337227,899290,870329,290Consolidated net income (loss)

    $   12,815,379$(12,262,768)$   5,929,528$(48,538,903)Net loss attributable to noncontrolling interest

    538,892316,7661,892,0961,199,161 Net income (loss) attributable to Optimer Pharmaceuticals, Inc. common stockholders

    $   13,354,271$(11,946,002)$   7,821,624$(47,339,742)Net income (loss )per share attributable to common stockholders - basic

    (1.25)Net income (loss )per share attributable to common stockholders - diluted

    (1.25)Shares used to compute net income (loss) per share attributable to  common stockholders - basic

    46,668,31039,140,21445,622,16837,830,452Shares used to compute net income (loss) per share attributable to  common stockholders - diluted

    47,527,76639,140,21446,369,68337,830,452Optimer Pharmaceuticals, Inc.Consolidated Balance SheetsYear Ended December 31,20112010ASSETSCurrent assets:Cash and cash equivalents

    $   31,787,512$  19,861,924Short-term investments

    78,791,06629,553,506Trade accounts receivable, net

    6,563,645-Accounts receivable, other


    3,947,380-Prepaid expenses and other current assets

    3,781,830463,307Total current assets

    177,160,72349,932,289Property and equipment, net

    2,590,715697,683Long-term investments

    882,000882,000Other assets

    1,389,734508,190Total assets

    $ 182,023,172$  52,020,162LIABILITIES  AND STOCKHOLDERS'  EQUITYCurrent liabilities:Accounts payable

    2,307,820Accrued expenses

    21,447,5442,385,046Total current liabilities

    $   31,308,006$
    4,692,866Deferred rent

    151,141141,138Stockholders’ equity

    150,564,02547,186,158Total liabilities and stockholders’ equity

    $ 182,023,172$  52,020,162

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
    2. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
    3. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
    4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    6. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
    7. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
    8. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
    9. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
    10. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
    11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    (Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
    (Date:10/9/2015)... 9, 2015 Eli Lilly and Company (NYSE: ... and approximately 50 new jobs to its research and development ... New York, New York . ... space will include a translational immuno-oncology hub and a Lilly ... collaborative access to cutting-edge drug discovery capabilities, including chemistry and ...
    (Date:10/9/2015)...   --> --> Phase ... San Diego, California , by Dr. Tom Lyon , ... Center, on 9 th October 2015 at 8:30a.m. PDT. ... Tom Lyon , Director of Orthopaedics and Chief of Orthopaedic Trauma, ... 8:30a.m. PDT. --> Kuros Biosurgery AG, a biotechnology company ...
    Breaking Medicine Technology:
    ... Talecris Biotherapeutics (Nasdaq: TLCR ) today ... Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more ... manufacturing technology. , Like PROLASTIN, the market leader ... the treatment of alpha1-antitrypsin (AAT) deficiency, a genetic ...
    ... BRIDGEWATER, N.J., Oct. 16 Sanofi-aventis U.S. announced that ... marketing approval for Elitek® (rasburicase) to be used for ... in adult patients with leukemia, lymphoma, and solid tumor ... in tumor lysis syndrome (TLS) and subsequent elevations of ...
    Cached Medicine Technology:
    (Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
    (Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. This pack comes with 60 vibrant CUBE LUT files. , ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In ... the risk of dying in reported home fires in half. As part of Fire ... alarms are property installed and maintained. , Half of home fire deaths result from ...
    (Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Head ... Center for the elite developmental camp at the Karolyi Ranch in Huntsville, Texas on ... Katreece Stone, Head Over Heels girls team head coach and executive director, said. “It's ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation ... for Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved ... been awarded a project by the CDC and allows AAFA to continue vital efforts ...
    Breaking Medicine News(10 mins):
    ... and about 150 die every year. // ... Medicine in New York recently analyzed 31 allergy deaths. They ... teenagers or young adults. They were away from home when ... ,"We were surprised that so few people had gotten correct ...
    ... papers published in The Lancet on adolescent health, the current ... parents.// The infections of the earlier times like polio and ... drug abuse etc. The only silver lining to this issue ... ,Obesity in adolescents has increased fourfold between 1970 and ...
    ... the heart disease medicine of Sanofi-Aventis will be made indigenously ... Tuesday.// ,As per the offer made by Sanofa-Aventis, ... imitated version of the drug. The statement released by the ... will benefit the poorer Thai patients. According to a health ...
    ... be the latest trend which is making waves in the ... develop their skills to make sure the evaluation of the ... ,More than 170 physician performance measures have been ... Physician Consortium for Performance Improvement organized by the American Medical ...
    ... has asked the aerated drink manufacturers Pepsico and Coca Cola ... The Ganguly report had deduced that pesticide residues were found ... should be furnished within six weeks. ,Centre ... public interest litigation which stated that that the cola drinks ...
    ... computed tomography (CT) screening plays a vital role in ... screening determines how early the cancer is diagnosed. This ... treatment which can be curative,” said NY-ELCAP principal investigator ... Weill Cornell Medical College and chief of the divisions ...
    Cached Medicine News:
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: